Home
About
Overview
Sharing Data
ORCID
Help
History (66)
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
Value-Based Medicine and Integration of Tumor Biology.
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines.
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
See All 66 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016 Feb 26; 8(2):e513.
View in:
PubMed
authors with profiles
Ravi Salgia
Randy Sweis